- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03119883
Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma
Dysregulation of Glutamine Utilization in the Pathogenesis of Multiple Myeloma
Study Overview
Status
Detailed Description
PRIMARY OBJECTIVE:
I. Compare the glutamine anaplerosis activity in bone marrow clonal plasma cells (cPCs) between patients with MGUS and MM using an in vivo and an ex vivo approach.
SECONDARY OBJECTIVES:
I. Compare the tricarboxylic acid (TCA) isotopomer enrichment in the bone marrow plasma obtained from patients with MGUS and MM with the in vivo approach.
II. Determine the peripheral blood enrichment of 13C in the TCA cycle intermediates from patients with MGUS and MM with the in vivo approach.
OUTLINE: Patients are assigned to 1 of 2 groups.
GROUP I (EX-VIVO): After an overnight fast of 6 hours, patients undergo collection of blood samples.
GROUP II (IN VIVO): After an overnight fast of 6 hours, patients receive 13-carbon labeled glutamine or 13-carbon-labeled glucose intravenously (IV) over 90 minutes. Patients also undergo collection of blood and bone marrow aspirate samples.
After completion of study, patient are followed up for 4 weeks.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Clinical Trials Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic in Rochester
-
Principal Investigator:
- Wilson I. Gonsalves, M.D.
-
Contact:
- Clinical Trials Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- At least 18 years of age
- International Myeloma Working Group (IMWG) criteria for the diagnosis of either MGUS or MM
Exclusion Criteria:
- Unable to provide consent
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) > 3
- Hemoglobin < 8 g/dL
- Women who are pregnant
- Prior history of adverse events with conscious sedation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group I (biospecimen collection)
EX-VIVO: After an overnight fast of 6 hours, patients undergo collection of bone marrow aspirate samples.
|
Undergo collection of blood
Other Names:
Undergo collection of bone marrow aspirate samples
Other Names:
|
Experimental: Group II (biospecimen collection, glutamine, glucose)
IN VIVO: After an overnight fast of 6 hours, patients receive 13-carbon labeled glutamine or 13-carbon-labeled glucose IV over 90 minutes.
Patients also undergo collection of blood and bone marrow aspirate samples.
|
Undergo collection of blood
Other Names:
Given IV
Other Names:
Undergo collection of bone marrow aspirate samples
Other Names:
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent enrichment of 13-Carbon in the tricarboxylic acid (TCA) cycle intermediates within bone marrow plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma
Time Frame: Up to 1 day
|
Will compare the glutamine anaplerosis activity in bone marrow clonal plasma cells between patients with MGUS and multiple myeloma.
|
Up to 1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent enrichment of 13-Carbon in the TCA cycle intermediates within bone marrow plasma from patients with MGUS and multiple myeloma
Time Frame: Up to 1 day
|
Will compare the glutamine anaplerosis activity in the plasma cells by assessing the bone marrow plasma between patients with MGUS and multiple myeloma.
|
Up to 1 day
|
Percent enrichment of 13-Carbon in the TCA cycle intermediates within the peripheral blood plasma from patients with MGUS and multiple myeloma
Time Frame: Up to 1 day
|
Will compare the peripheral blood enrichment of 13-carbon in the TCA cycle intermediates from patients with MGUS and multiple myeloma.
|
Up to 1 day
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Wilson I Gonsalves, M.D., Mayo Clinic in Rochester
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Blood Protein Disorders
- Hypergammaglobulinemia
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Paraproteinemias
- Monoclonal Gammopathy of Undetermined Significance
Other Study ID Numbers
- 17-003133
- P30CA015083 (U.S. NIH Grant/Contract)
- NCI-2021-02642 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Monoclonal Gammopathy of Undetermined Significance
-
RxCelerate LtdRxCelerate LimitedUnknownMonoclonal Gammopathy of Unknown SignificanceUnited Kingdom
-
Dartmouth-Hitchcock Medical CenterCelgene CorporationTerminatedNeuropathy | Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)United States
-
University of Milano BicoccaCompletedMonoclonal Gammopathy of Renal SignificanceItaly
-
Rennes University HospitalCompletedMyeloma | Monoclonal Gammopathy | Monoclonal Gammopathy of Undetermined SignificationFrance
-
Academia Nacional de MedicinaUnknownMonoclonal Gammopathy of Renal SignificanceArgentina
-
Regeneron PharmaceuticalsNot yet recruitingMonoclonal Gammopathy of Undetermined Significance (MGUS) | Smoldering Multiple Myeloma (SMM)
-
Columbia UniversityGenzyme, a Sanofi CompanyRecruitingMonoclonal GammopathyUnited States
-
UMC UtrechtBeiGeneNot yet recruitingMonoclonal Gammopathy of Uncertain SignificanceNetherlands
-
University of MiamiWithdrawnObesity | Overweight | Monoclonal Gammopathies
-
Peking University First HospitalRecruitingMultiple Myeloma | Amyloidosis | Smoldering Multiple Myeloma | Plasma Cell Leukemia | Cryoglobulinemia | Light Chain Deposition Disease | Castleman's Disease | Heavy Chain Deposition Disease | Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes | Monoclonal Gammopathy of Undetermined... and other conditionsChina
Clinical Trials on Biospecimen Collection
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingBreast Adenocarcinoma | HER2-Positive Breast CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditionsUnited States, Puerto Rico
-
LLS PedAL Initiative, LLCNational Cancer Institute (NCI); Children's Oncology GroupRecruitingAcute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Myeloid Leukemia Associated With Down Syndrome | Mixed Phenotype Acute Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy | Myelodysplastic Syndrome Post Cytotoxic TherapyUnited States, Canada, Australia, Puerto Rico, New Zealand
-
Thomas Jefferson UniversityNational Cancer Institute (NCI)Active, not recruiting
-
Mayo ClinicRecruitingEarly Stage Breast Carcinoma | Chemotherapy-Related Nausea and/or VomitingUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruiting
-
Ohio State University Comprehensive Cancer CenterGuardant Health, Inc.RecruitingColorectal CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterRecruitingCholangiocarcinoma | Malignant Digestive System NeoplasmUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Recruiting